echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Orphan Drug Weekly. Multiple gastric cancer treatments on the list! Amin's dual-specific antibodies were shortlisted.

    Orphan Drug Weekly. Multiple gastric cancer treatments on the list! Amin's dual-specific antibodies were shortlisted.

    • Last Update: 2020-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Drugs: Telomelysin (OBP-301) Research and Development: Oncolys BioPharma Therapeutic Diseases: Esophageal Cancer Introduction: Telomelysin is a genetically engineered type 5 adenovirus that specifically replicates and destroys cancer cells within cancer cells.
    Telomelysin has the potential to induce strong antitumor activity after specific replication in cancer cells causes tumor dissolution, and is safe due to its low replication in normal cells.
    no serious adverse reactions such as vomiting, hair loss and hematopoietic disorders have occurred in the clinical studies conducted, and are expected to improve the quality of life (QOL) in patients.
    recent studies have shown that cancer cells destroyed by viral therapy may enhance cancer immunity by directly transmitting signals of their specific antigens to immune cells such as dendritic cells.
    , the company is preparing to combine Telomelysin with an immune checkpoint inhibitor such as anti-PD-1 antibody to give it systemic anti-cancer effects and good local control.
    the official website shows that it is in clinical phase 2 study.
    Drugs: REN001 Research and Development: Reneo Pharmaceuticals Therapeutic Disease: Primary mitochondrial myopathia (Primary mitochondrial myopathies, PMMs) Introduction: Primary mitomitomitomitomamyopathy is a rare and often life-threatening disease caused by genetic mutations in the mitochondria.
    PMMs can appear at any age, and symptoms include muscle pain, weakness, cramps, and muscle atrophy, which can be accompanied by inactivity intolerance, difficulty swallowing, and severe muscle tissue decomposition with the dissolution of the transverse muscle.
    currently, there is no approved treatment.
    REN001 is a selective PPAR agonisthate that controls many genes associated with mitochondrial activity.
    Reneo Pharmaceuticals aims to improve cellular energy metabolism by enhancing mitochondria and potentially increasing the number of mitochondria.
    July 2019, the FDA also granted the drug orphan drug for the drug to treat fatty acid oxidation disorder (FAOD).
    Drugs: AMG199 Research and Development: Amgen Treatment Diseases: Gastric Cancer (including gastroesophageal binding cancer) Introduction: AMG199 is a bispecific antibody targeting MUC17/CD3.
    the drug consists of two single-stranded variable fragments (scFv), one for tumor-related antigens (TAA) human viscoprotein 17 (MUC17), and one for human CD3 (t lymphocytes found on a T-cell surface antigen), with potential antitumor activity.
    administration, AMG199 binds to CD3 on T cells and MUC17 expressed on tumor cells, causing T-cells to cross-link with tumor cells, and inducing a strong cytotoxic T lymphocyte (CTL) response to tumor cells expressing MUC17.
    website shows that it is in the first phase of clinical studies on metastatic gastric cancer and gastroesophageal connectivity cancer.
    Drugs: Progesterone Research and Development: GLIA Therapeutic Disease: Eye TransplantAnti-Host Disease Introduction: Progesterone is a female hormone that is important for regulating ovulation and menstruation.
    progesterone can be used for menstruation in women who have not yet menopause but are dehumanated but lack of progesterone in the body, and is also used to prevent overgrowth of the uterine wall of postmenopausal women who are receiving estrogen replacement therapy.
    Drugs: Margetuximab Research and Development: MacroGenics Treatment Disease: Gastric Cancer and Gastric Esophageal Connection Sylls: Margetuximab is a fc-modified monoclonal antibody that targets the HER2 protein.
    HER2 is expressed by tumor cells in solid tumors such as breasts and gastroesophageal tubes.
    Margetuximab is designed to block HER2, with HER2 binding and anti-proliferation effects similar to qural monituate.
    in addition, the company has revamped margetuximab to enhance the immune system's involvement with macroGenics' Fc optimization technology.
    Margetuximab's phase 2/3 MAHOGANY trial for treatment of HER2-positive gastroesophageal cancer patients is under way, while the Bioproduct Licensing Application (BLA) for margetuximab combined chemotherapy treatment for metastatic HER2-positive breast cancer patients is under FDA review, with pDUFA target date december 18, 2020.
    Drugs: AAV9 Carrier Carrying CLN5 Genetic Ally Therapy Research and Development Enterprise: Neurogene Therapeutic Disease: Neuron Wax-like Lipid Brown Deposition Type 5 (neuronal ceroid lipofsosis type 5) Introduction: Neuron Wax-like Lipid Brown Plasmic Deposition Disease (NCL), also known as Batten disease, is a family of rare and fatal neurodegenerative diseases caused by a series of gene-causing changes that cause toxic deposits to accumulate in multiple organ systems, including the brain, eyes, skin, and other cells.
    Neurogene focuses on the development of innovative gene therapies for rare neurological diseases, including midday auremidolamine (AGU) and fibulaaa (CMT).
    drugs: Tacrolimus: Ophtho-Therapeutics Treatment Disease: Spring Keratoconjunctivitis Profile: Tacros is a large cyclostere immunosuppressant produced by Streptomys tsukubaens.
    clinical experiments show that it has a good effect in heart, lung, intestine, bone marrow and other transplantation.
    also play an active role in the treatment of autoimmune diseases such as aspecific dermatitis (AD), systemic lupus erythematosus (SLE), autoimmune eye disease and so on.
    Drugs: Sivelestat Research and Development: RNR BioMedical Treatment Diseases: Gastric Cancer Introduction: Severes is a competitive inhibitor of human neutrophil elastinase, which also inhibits white blood cell elastinase in rabbits, rats, hamsters, and mice.
    in the in vivo study, Sivilestos inhibited hamster pulmonary bleeding through intratube administration, and intravenous administration increased the porpoise of capillaries in guinea pigs, both of which were induced by human neutrophil elastinase.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.